56 research outputs found

    Latin American Thyroid Society Recommendations For The Management Of Thyroid Nodules [recomendações Da Sociedade Latino-americana De Tireoide No Manejo De Nódulos Tireoideos]

    Get PDF
    Several guidelines on diagnosis and treatment of thyroid nodules and cancer have recently been published. However, recommended practices are not always appropriate to different settings or countries. The aim of this consensus was to develop Clinical Guidelines for evaluation and management of patients with thyroid nodules applicable to Latin American countries. The panel was composed by 13 members of the Latin American Thyroid Society involved with research and management of thyroid nodules and cancer from different medical centers in Latin America. The consensus was produced based on the expert opinion of the panel with use of principles of evidence-based medicine. Following a group meeting, a first draft based on the expert opinion of the panel was elaborated and later circulated among panel members for further revision. After revision, this document was submitted to all LATS members for commentaries and considerations and finally revised and refined by the authors. The final recommendations represent state of the art on management of thyroid nodules applied to all Latin American countries. © ABE&M todos os direitos reservados.53911671175Villena, J., Pretell, E., Bocio nodular tóxico en pacientes de zonas yodo deficientes y de la costa (1991) Rev Méd Hered, 2 (4), pp. 149-155Villena, J., Ferrufino, J.C., Klinge, G., Nódulo tireoideo frio. Características clínicas y anatomopatológicas en pacientes migrantes de zonas con deficiencia de yodo y de la costa (1993) Rev Méd Hered, 4 (4), pp. 188-193Harach, H.R., Ceballos, G.A., Thyroid cancer, thyroiditis and dietary iodine: A review based on the Salta, Argentina model (2008) Endocr Pathol, 19 (4), pp. 209-220Pretell, E.A., Delange, F., Hostalek, U., Corigliano, S., Barreda, L., Higa, A.M., Iodine nutrition improves in Latin America (2004) Thyroid, 14 (8), pp. 595-604Harach, H.R., Franssila, K.O., Wasenius, V.M., Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study (1985) Cancer, 56 (3), pp. 531-538Rosai, J., Livolsi, V.A., Sobrinho-Simoes, M., Williams, E.D., Renaming papillary microcarcinoma of the thyroid gland: The Porto proposal (2003) Int J Surg Pathol, 11 (4), pp. 249-251Hay, I.D., Grant, C.S., van Heerden, J.A., Goellner, J.R., Ebersold, J.R., Bergstralh, E.J., Papillary thyroid microcarcinoma: A study of 535 cases observed in a 50-year period (1992) Surgery, 112 (6), pp. 1139-1146Jukkola, A., Bloigu, R., Ebeling, T., Salmela, P., Blanco, G., Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications (2004) Endocr Relat Cancer, 11 (3), pp. 571-579Passler, C., Scheuba, C., Prager, G., Kaczirek, K., Kaserer, K., Zettinig, G., Prognostic factors of papillary and follicular thyroid cancer: Differences in an iodine-replete endemic goiter region (2004) Endocr Relat Cancer, 11 (1), pp. 131-139Rossi, R., Roti, E., Trasforini, G., Pansini, G., Cavazzini, L., Zatelli, M.C., Differentiated thyroid cancers 11-20 mm in diameter have clinical and histopathologic characteristics suggesting higher aggressiveness than those ≤ 10 mm (2008) Thyroid, 18 (3), pp. 309-315Curtis, R.E., Rowlings, P.A., Deeg, H.J., Shriner, D.A., Socie, G., Travis, L.B., Solid cancers after bone marrow transplantation (1997) N Engl J Med, 336 (13), pp. 897-904Sippel, R.S., Caron, N.R., Clark, O.H., An evidence-based approach to familial nonmedullary thyroid cancer: Screening, clinical management, and follow-up (2007) World J Surg, 31 (5), pp. 924-933Pacini, F., Pinchera, A., Giani, C., Grasso, L., Doveri, F., Baschieri, L., Serum thyroglobulin in thyroid carcinoma and other thyroid disorders (1980) J Endocrinol Invest, 3 (3), pp. 283-292Niccoli, P., Wion-Barbot, N., Caron, P., Henry, J.F., de Micco, C., Saint Andre, J.P., Interest of routine measurement of serum calcitonin: Study in a large series of thyroidectomized patients. The French Medullary Study Group (1997) J Clin Endocrinol Metab, 82 (2), pp. 338-341Gagel, R.F., Hoff, A.O., Cote, G.J., Medullary thyroid carcinoma (2005) Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text, pp. 967-988. , In: Lewis E, Robert D, Sidney H, Sidney C, (Eds)., Philadelphia: Lippincott Williams and WilkinsPapini, E., Guglielmi, R., Bianchini, A., Crescenzi, A., Taccogna, S., Nardi, F., Risk of malignancy in nonpalpable thyroid nodules: Predictive value of ultrasound and color-Doppler features (2002) J Clin Endocrinol Metab, 87 (5), pp. 1941-1946Camargo, R.Y., Tomimori, E.K., Knobel, M., Medeiros-Neto, G., Preoperative assessment of thyroid nodules: Role of ultrasonography and fine needle aspiration biopsy followed by cytology (2007) Clinics, 62 (4), pp. 411-418Kang, H.W., No, J.H., Chung, J.H., Min, Y.K., Lee, M.S., Lee, M.K., Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas (2004) Thyroid, 14 (1), pp. 29-33Shimura, H., Haraguchi, K., Hiejima, Y., Fukunari, N., Fujimoto, Y., Katagiri, M., Distinct diagnostic criteria for ultrasonographic examination of papillary thyroid carcinoma: A multicenter study (2005) Thyroid, 15 (3), pp. 251-258Cappelli, C., Castellano, M., Pirola, I., Cumetti, D., Agosti, B., Gandossi, E., The predictive value of ultrasound findings in the management of thyroid nodules (2007) Qjm, 100 (1), pp. 29-35Holden, A., The role of colour and duplex Doppler ultrasound in the assessment of thyroid nodules (1995) Australas Radiol, 39 (4), pp. 343-349Papini, E., Guglielmi, R., Bianchini, A., Crescenzi, A., Taccogna, S., Nardi, F., Risk of malignancy in nonpalpable thyroid nodules: Predictive value of ultrasound and color-Doppler features (2002) J Clin Endocrinol Metab, 87 (5), pp. 1941-1946Chammas, M.C., Gerhard, R., de Oliveira, I.R., Widman, A., de Barros, N., Durazzo, M., Thyroid nodules: Evaluation with power Doppler and duplex Doppler ultrasound (2005) Otolaryngol Head Neck Surg, 132 (6), pp. 874-882Frates, M.C., Benson, C.B., Doubilet, P.M., Cibas, E.S., Marqusee, E., Can color Doppler sonography aid in the prediction of malignancy of thyroid nodules? (2003) J Ultrasound Med, 22 (2), pp. 127-131Rago, T., Vitti, P., Chiovato, L., Mazzeo, S., de Liperi, A., Miccoli, P., Role of conventional ultrasonography and color flow-doppler sonography in predicting malignancy in 'cold' thyroid nodules (1998) Eur J Endocrinol, 138 (1), pp. 41-46Lyshchik, A., Moses, R., Barnes, S.L., Higashi, T., Asato, R., Miga, M.I., Quantitative analysis of tumor vascularity in benign and malignant solid thyroid nodules (2007) J Ultrasound Med, 26 (6), pp. 837-846Tamsel, S., Demirpolat, G., Erdogan, M., Nart, D., Karadeniz, M., Uluer, H., Power Doppler US patterns of vascularity and spectral Doppler US parameters in predicting malignancy in thyroid nodules (2007) Clin Radiol, 62 (3), pp. 245-251Pacini, F., Burroni, L., Ciuoli, C., di Cairano, G., Guarino, E., Management of thyroid nodules: A clinicopathological, evidence-based approach (2004) Eur J Nucl Med Mol Imaging, 31 (10), pp. 1443-1449Kim, T.Y., Kim, W.B., Ryu, J.S., Gong, G., Hong, S.J., Shong YK. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: High prevalence of malignancy in thyroid PET incidentaloma (2005) Laryngoscope, 115 (6), pp. 1074-1078Danese, D., Sciacchitano, S., Farsetti, A., Andreoli, M., Pontecorvi, A., Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules (1998) Thyroid, 8 (1), pp. 15-21de la Serna Saravia, C., Cuellar, F., Accuracy of aspiration cytology in thyroid cancer: A study in 1 institution (2006) Acta Cytol, 50 (4), pp. 384-387Giorgadze, T., Rossi, E.D., Fadda, G., Gupta, P.K., Livolsi, V.A., Baloch, Z., Does the fine-needle aspiration diagnosis of "Hurthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy? (2004) Diagn Cytopathol, 31 (5), pp. 307-312Niepomniszcze, H., Garcia, A., Faure, E., Castellanos, A., del Carmen Zalazar, M., Bur, G., Long-term follow-up of contralateral lobe in patients hemithyroidectomized for solitary follicular adenoma (2001) Clin Endocrinol (oxf), 55 (4), pp. 509-513Alcantara-Jones, D.M., Araujo, L.M., Almeida, A.M., Jones, D.A., Cardoso, L.J., Passos, M.C., Percutaneous ethanol injection for the treatment of thyroid nodules (2006) Arq Bras Endocrinol Metabol, 50 (1), pp. 97-104Lippi, F., Ferrari, C., Manetti, L., Rago, T., Santini, F., Monzani, F., Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: Results of an Italian multicenter study. The Multicenter Study Group (1996) J Clin Endocrinol Metab, 81 (9), pp. 3261-3264Hegedüs, L., Hansen, B.M., Knudsen, N., Hansen, J.M., Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre (1988) Bmj, 297 (6649), pp. 661-662Huysmans, D., Hermus, A., Edelbroek, M., Barentsz, J., Corstens, F., Kloppenborg, P., Radioiodine for nontoxic multinodular goiter (1997) Thyroid, 7 (2), pp. 235-239Nygaard, B., Hegedus, L., Ulriksen, P., Nielsen, K.G., Hansen, J.M., Radioiodine therapy for multinodular toxic goiter (1999) Arch Intern Med, 159 (12), pp. 1364-1368Huysmans, D.A., Hermus, A.R., Corstens, F.H., Barentsz, J.O., Kloppenborg, P.W., Large, compressive goiters treated with radioiodine (1994) Ann Intern Med, 121 (10), pp. 757-762Nygaard, B., Soes-Petersen, U., Hoilund-Carlsen, P.F., Veje, A., Holst, P.E., Vestergaard, A., Improvement of upper airway obstruction after 131I-treatment of multinodular nontoxic goiter evaluated by flow volume loop curves (1996) J Endocrinol Invest, 19 (2), pp. 71-75Nygaard, B., Faber, J., Hegedus, L., Acute changes in thyroid volume and function following 131I therapy of multinodular goitre (1994) Clin Endocrinol (oxf), 41 (6), pp. 715-718Huysmans, D.A., Nieuwlaat, W.A., Erdtsieck, R.J., Schellekens, A.P., Bus, J.W., Bravenboer, B., Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter (2000) J Clin Endocrinol Metab, 85 (10), pp. 3592-3596Nieuwlaat, W.A., Hermus, A.R., Sivro-Prndelj, F., Corstens, F.H., Huysmans, D.A., Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters (2001) J Clin Endocrinol Metab, 86 (11), pp. 5330-5336Nieuwlaat, W.A., Huysmans, D.A., van den Bosch, H.C., Sweep, C.G., Ross, H.A., Corstens, F.H., Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter (2003) J Clin Endocrinol Metab, 88 (7), pp. 3121-3129Duick, D.S., Baskin, H.J., Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters (2003) Endocr Pract, 9 (3), pp. 204-209Silva, M.N., Rubio, I.G., Romao, R., Gebrin, E.M., Buchpiguel, C., Tomimori, E., Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres (2004) Clin Endocrinol (oxf), 60 (3), pp. 300-308Albino, C.C., Mesa Jr., C.O., Olandoski, M., Ueda, C.E., Woellner, L.C., Goedert, C.A., Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine (2005) J Clin Endocrinol Metab, 90 (5), pp. 2775-2780Friguglietti, C.U., Lin, C.S., Kulcsar, M.A., Total thyroidectomy for benign thyroid disease (2003) Laryngoscope, 113 (10), pp. 1820-1826Rezzonico, J., Rezzonico, M., Pusiol, E., Pitoia, F., Neipomniszcze, H., Introducing the thyroid gland as another victim of the insulin resistance syndrome (2008) Thyroid, 18 (4), pp. 461-464Vella, V., Sciacca, L., Pandini, G., Mineo, R., Squatrito, S., Vigneri, R., The IGF system in thyroid cancer: New concepts (2001) Mol Pathol, 54 (3), pp. 121-124Rezzonico, J., Rezzonico, M., Pusiol, E., Pitoia, F., Neipomniszcze, H., 2008 Metformin treatment of benign thyroid nodules in euthytoid patients with insulin resistance (2008) Diabetes Vasc Dis Reas, 5, p. 223Papini, E., Guglielmi, R., Bizzarri, G., Graziano, F., Bianchini, A., Brufani, C., Pacella, S., Pacella, C.M., Treatment of benign cold thyroid nodules: A randomized clinical trial of percutaneous lases ablation versus levothyroxine therapy or follow-up (2007) Thyroid, pp. 229-235Spiezia, S., Garberoglio, R., Milone, F., Ramundo, V., Caiazzo, C., Assanti, A.P., Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation (2009) Thyroid, 19 (3), pp. 219-225Alexander, E.K., Hurwitz, S., Heering, J.P., Benson, C.B., Frates, M.C., Doubilet, P.M., Natural history of benign solid and cystic thyroid nodules (2003) Ann Intern Med, 138 (4), pp. 315-318Carmeci, C., Jeffrey, R.B., McDougall, I.R., Nowels, K.W., Weigel, R.J., Ultrasound-guided fine-needle aspiration biopsy of thyroid masses (1998) Thyroid, 8 (4), pp. 283-289Ylagan, L.R., Farkas, T., Dehner, L.P., Fine needle aspiration of the thyroid: A cytohistologic correlation and study of discrepant cases (2004) Thyroid, 14 (1), pp. 35-41Hung, W., Anderson, K.D., Chandra, R.S., Kapur, S.P., Patterson, K., Randolph, J.G., Solitary thyroid nodules in 71 children and adolescents (1992) J Pediatr Surg, 27 (11), pp. 1407-1409Yip, F.W., Reeve, T.S., Poole, A.G., Delbridge, L., Thyroid nodules in childhood and adolescence (1994) Aust N Z J Surg, 64 (10), pp. 676-678Hegedus, L., Clinical practice. The thyroid nodule (2004) N Engl J Med, 351 (17), pp. 1764-1771Niedziela, M., Pathogenesis, diagnosis and management of thyroid nodules in children (2006) Endocr Relat Cancer, 13 (2), pp. 427-453Degnan, B.M., McClellan, D.R., Francis, G.L., An analysis of fine-needle aspiration biopsy of the thyroid in children and adolescents (1996) J Pediatr Surg, 31 (7), pp. 903-907Lugo-Vicente, H., Ortiz, V.N., Irizarry, H., Camps, J.I., Pagan, V., Pediatric thyroid nodules: Management in the era of fine needle aspiration (1998) J Pediatr Surg, 33 (8), pp. 1302-1305Corrias, A., Einaudi, S., Chiorboli, E., Weber, G., Crino, A., Andreo, M., Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: Comparison with conventional clinical, laboratory, and imaging approaches (2001) J Clin Endocrinol Metab, 86 (10), pp. 4644-4648Amrikachi, M., Ponder, T.B., Wheeler, T.M., Smith, D., Ramzy, I., Thyroid fine-needle aspiration biopsy in children and adolescents: Experience with 218 aspirates (2005) Diagn Cytopathol, 32 (4), pp. 189-192Gharib, H., Papini, E., Valcavi, R., Baskin, H.J., Crescenzi, A., Dottorini, M.E., Duick, D.S., Zini, M., AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules (2006) Endocr Pract, 12 (1), pp. 63-102Wiersinga, W.M., Management of thyroid nodules in children and adolescents (2007) Hormones (athens), 6 (3), pp. 194-199Moosa, M., Mazzaferri, E.L., Outcome of differentiated thyroid cancer diagnosed in pregnant women (1997) J Clin Endocrinol Metab, 82 (9), pp. 2862-286

    Pemphigus autoimmunity: Hypotheses and realities

    Get PDF
    The goal of contemporary research in pemphigus vulgaris and pemphigus foliaceus is to achieve and maintain clinical remission without corticosteroids. Recent advances of knowledge on pemphigus autoimmunity scrutinize old dogmas, resolve controversies, and open novel perspectives for treatment. Elucidation of intimate mechanisms of keratinocyte detachment and death in pemphigus has challenged the monopathogenic explanation of disease immunopathology. Over 50 organ-specific and non-organ-specific antigens can be targeted by pemphigus autoimmunity, including desmosomal cadherins and other adhesion molecules, PERP cholinergic and other cell membrane (CM) receptors, and mitochondrial proteins. The initial insult is sustained by the autoantibodies to the cell membrane receptor antigens triggering the intracellular signaling by Src, epidermal growth factor receptor kinase, protein kinases A and C, phospholipase C, mTOR, p38 MAPK, JNK, other tyrosine kinases, and calmodulin that cause basal cell shrinkage and ripping desmosomes off the CM. Autoantibodies synergize with effectors of apoptotic and oncotic pathways, serine proteases, and inflammatory cytokines to overcome the natural resistance and activate the cell death program in keratinocytes. The process of keratinocyte shrinkage/detachment and death via apoptosis/oncosis has been termed apoptolysis to emphasize that it is triggered by the same signal effectors and mediated by the same cell death enzymes. The natural course of pemphigus has improved due to a substantial progress in developing of the steroid-sparing therapies combining the immunosuppressive and direct anti-acantholytic effects. Further elucidation of the molecular mechanisms mediating immune dysregulation and apoptolysis in pemphigus should improve our understanding of disease pathogenesis and facilitate development of steroid-free treatment of patients

    Selective use of sorafenib in the treatment of thyroid cancer

    No full text
    Fabián Pitoia, Fernando Jerkovich Division of Endocrinology, Hospital de Clinicas – University of Buenos Aires, Buenos Aires, Argentina Abstract: Sorafenib is a multiple kinase inhibitor (MKI) approved for the treatment of primary advanced renal cell carcinoma and advanced primary liver cancer. It was recently approved by several health agencies around the world as the first available MKI treatment for radioactive iodine-refractory advanced and progressive differentiated thyroid cancer. Sorafenib targets C-RAF, B-RAF, VEGF receptor-1, -2, -3, PDGF receptor-β, RET, c-kit, and Flt-3. As a multifunctional inhibitor, sorafenib has the potential of inhibiting tumor growth, progression, metastasis, and angiogenesis and downregulating mechanisms that protect tumors from apoptosis and has shown to increase the progression-free survival in several Phase II trials. This led to the Phase III trial (DECISION) which showed that there was an improvement in progression-free survival of 5 months for patients on sorafenib when compared to those on placebo. Adverse events with this drug are common but usually manageable. The development of resistance after 1 or 2 years is almost a rule in most patients who showed partial response or stabilization of the disease while on sorafenib, which makes it necessary to think of a plan for subsequent therapies. These may include the use of another MKI, such as lenvatinib, the second approved MKI for advanced differentiated thyroid cancer, or include patients in clinical trials or the off-label use of other MKIs. Given sorafenib’s earlier approval, most centers now have access to its prescription. The goal of this review was to improve the care of these patients by describing key aspects that all prescribers will need to master in order to optimize outcomes. Keywords: multiple kinase inhibitor, differentiated thyroid cancer, progression-free survival, radioiodin

    Non-specific autoantibodies in pemphigus vulgaris

    No full text
    corecore